The management of portal hypertension has long been challenged by the limitations of invasive diagnostic methods.While hepatic venous pressure gradient(HVPG)measurement remains the gold standard for diagnosing clinica...The management of portal hypertension has long been challenged by the limitations of invasive diagnostic methods.While hepatic venous pressure gradient(HVPG)measurement remains the gold standard for diagnosing clinically significant portal hypertension(CSPH),its invasiveness and limited availability have necessitated the development of reliable,non-invasive alternatives(1,2).This need is particularly pressing given that CSPH represents a critical milestone in chronic liver disease progression,marking the threshold beyond which patients face increased risks of variceal bleeding and hepatic decompensation.展开更多
基金supported by the Soonchunhyang University Research Fund.
文摘The management of portal hypertension has long been challenged by the limitations of invasive diagnostic methods.While hepatic venous pressure gradient(HVPG)measurement remains the gold standard for diagnosing clinically significant portal hypertension(CSPH),its invasiveness and limited availability have necessitated the development of reliable,non-invasive alternatives(1,2).This need is particularly pressing given that CSPH represents a critical milestone in chronic liver disease progression,marking the threshold beyond which patients face increased risks of variceal bleeding and hepatic decompensation.
